In addition, expanded immune profiling that includes tumor mutation burden, albeit no correlation with PD-L1 staining in this study, would be of interest given emerging data on synergy of checkpoint inhibition with CDK 4/6 inhibition25. This evidence concerns the gene CD274 and neoplasm.